

	Overall (N=681)	Death within 30 days	
		Yes (N=119)	No (N=562)
Age, years			
Median (IQR)	68 (59, 75)	69 (62, 75)	68 (59, 75)
Gender			
Female	307 (45.1%)	53 (44.5%)	254 (45.2%)
Male	374 (54.9%)	66 (55.5%)	308 (54.8%)
Cancer site			
Breast	70 (10.3%)	9 (7.6%)	61 (10.9%)
Central Nervous System	17 (2.5%)	3 (2.5%)	14 (2.5%)
Gastrointestinal	169 (24.8%)	22 (18.5%)	147 (26.2%)
Genitourinary	63 (9.3%)	7 (5.9%)	56 (10.0%)
Gynecologic	26 (3.8%)	2 (1.7%)	24 (4.3%)
Hematologic	140 (20.6%)	27 (22.7%)	113 (20.1%)
Head and neck	11 (1.6%)	1 (0.8%)	10 (1.8%)
Lung	145 (21.3%)	36 (30.3%)	109 (19.4%)
Melanoma	13 (1.9%)	5 (4.2%)	8 (1.4%)
Primary unknown	20 (2.9%)	4 (3.4%)	16 (2.8%)
Other	7 (1.0%)	3 (2.5%)	4 (0.7%)
Chemotherapy type			
Conventional	506 (74.3%)	88 (73.9%)	418 (74.4%)
Targeted/Immunotherapy	175 (25.7%)	31 (26.1%)	144 (25.6%)
Route of administration			
Intravenous/Subcutaneous	512 (75.2%)	84 (70.6%)	428 (76.2%)
Oral	169 (24.8%)	35 (29.4%)	134 (23.8%)
Palliative referral			
Yes	444 (65.2%)	53 (44.5%)	391 (69.6%)
No	237 (34.8%)	66 (55.5%)	171 (30.4%)
Time from diagnosis to palliative referral			
No referral	237 (34.8%)	66 (55.5%)	171 (30.4%)
<1 year	177 (26.0%)	29 (24.4%)	148 (26.3%)
1 to <3 years	162 (23.8%)	13 (10.9%)	149 (26.5%)
3+ years	105 (15.4%)	11 (9.2%)	94 (16.7%)
Intent of chemotherapy			
Palliative	579 (85.0%)	107 (89.9%)	472 (84.0%)
Neoadjuvant/Adjuvant	45 (6.6%)	4 (3.4%)	41 (7.3%)
Cure	57 (8.4%)	8 (6.7%)	49 (8.7%)
Line of chemotherapy			
1	459 (67.4%)	84 (70.6%)	375 (66.7%)
2	145 (21.3%)	19 (16.0%)	126 (22.4%)
3+	77 (11.3%)	16 (13.4%)	61 (10.9%)